Annual Report 2019
Division of Innovative Pathology and Laboratory Medicine (Kashiwa Campus)
Takeshi Kuwata, Masato Sugano, Shigeyuki Hasuo
Introduction
The Division of Innovative Pathology and Laboratory Medicine (IPLM) was established at the Exploratory Oncology Research and Clinical Trial Center (EPOC) in 2016. The aim of the LPMN is to develop new diagnostic technologies, reagents, and devices in the pathology and laboratory medicine field.
The Team and What We Do
To achieve our goal, the activities of the IPLM closely collaborate with the Department of Pathology and Clinical Laboratories in the National Cancer Center Hospital East (NCCHE) and the Division of Pathology as well as other divisions in the EPOC.
Research activities
We are conducting the DEF (Discovery and Establishment of new biomarkers For gastric cancer) study, in which patient-derived xenografts (PDX) and cell lines have been established from surgically resected gastric cancers as well ascites. The aim of this study is to establish reliable bio-resources for supporting activities of new drug development in academia as well as pharmaceuticals. By March 2020, we had successfully established a total of 36 gastric cancer PDX models and 32 novel gastric cancer cell lines (Figure 1 & 2).
Expression of selected receptor tyrosine-kinases as well as NGS-based gene mutation profiles have been evaluated in PDX and CDX models.
Education
We are participating in a weekly clinical conference with the Department of Pathology and Clinical Laboratories in the NCCHE. We also hold a biweekly progress research meeting in the EPOC as well as a monthly research meeting with the Division of Pathology in the EPOC. We presented our research data in scientific meetings including an annual meeting of the Japanese Society of Pathology and have published in well-recognized scientific journals.
Future prospects
Our goal is to develop new diagnostic technologies, reagents and devices required for providing precision medicine to all cancer patients. For this purpose, we will use our experience at the NCCHE and conduct translational/reverse-translational research. In collaboration with the Department of Pathology and Clinical Laboratories, we will also conduct genetic testing and provide a clinical sequence service in the NCCHE.
List of papers published in 2019
Journal
1. Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Ishii G, Kuwata T, Shitara K. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clin Cancer Res, 26:3784-3790, 2020
2. Sugita S, Kinoshita T, Kuwata T, Tokunaga M, Kaito A, Watanabe M, Tonouchi A, Sato R, Nagino M. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc, 2020
3. Tonouchi A, Sugano M, Tokunaga M, Sugita S, Watanabe M, Sato R, Kaito A, Akimoto T, Ochiai A, Kinoshita T, Kuwata T. Extra-perigastric Extranodal Metastasis is a Significant Prognostic Factor in Node-Positive Gastric Cancer. World J Surg, 43:2499-2505, 2019
4. Oki T, Aokage K, Ueda T, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Funai K, Tsuboi M, Ishii G. Proportion of goblet cell is associated with malignant potential in invasive mucinous adenocarcinoma of the lung. Pathol Int, 69:526-535, 2019
5. Omori T, Aokage K, Nakamura H, Katsumata S, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Ikeda N, Tsuboi M, Ishii G. Growth patterns of small peripheral squamous cell carcinoma of the lung and their impacts on pathological and biological characteristics of tumor cells. J Cancer Res Clin Oncol, 145:1773-1783, 2019
6. Suzuki J, Kojima M, Aokage K, Sakai T, Nakamura H, Ohara Y, Tane K, Miyoshi T, Sugano M, Fujii S, Kuwata T, Ochiai A, Ito M, Suzuki K, Tsuboi M, Ishii G. Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer. Virchows Arch, 474:569-575, 2019
7. Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer, 22:793-802, 2019
8. Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases, 7:1964-1977, 2019
9. Nishihara K, Oono Y, Kuwata T, Ikematsu H, Yano T. Depressed gastric-type adenoma in nonatrophic gastric mucosa without Helicobacter pylori infection. Endoscopy, 51:E138-E140, 2019
10. Oono Y, Kuwata T, Takashima K, Shinmura K, Hori K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. Gastric Cancer, 22:335-343, 2019